http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2499568-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c9303a2c93645d26a1c84fb810ca0bd |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-194 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M5-168 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-067 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B17-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61H39-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate | 2012-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a730242338f8913801af36e787d5e90a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fc4361e8686add0855d7ce57c6d2c96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1ee60ccb75a1ec5d21e1ddb0084ea7a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_964f1800ef1a8116740932a5d32d408b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc5b8a2b7b03a63fa0537e777fb54435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06bc47e1b5cb67fa282a19e53965e1f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2994f953b774a5ce00eb79404461efd1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97220f3098f649b2a7c28cde5059859f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2bc1f7b533d01ed553123e84b80c967 |
| publicationDate | 2013-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2499568-C1 |
| titleOfInvention | Method of preventing cardiovascular complications in patients with syndrome of endogenous intoxication against background of acute pyelonephritis in perioperative period |
| abstract | FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to anaesthesiology, resuscitation and urology, and can be applied for prevention of cardiovascular complications in patients with syndrome of endogenous intoxication against the background of acute purulent pyelonephritis in perioperative period. For this purpose reamberine 1.5% in dose 400 ml is introduced to patient from the moment of clinical diagnosis daily to the moment of performing operation. After that, in the process of operation, at the stage of kidney decapsulation infusion of reamberine in the same dose in combination with intravenous blood irradiation is realised, with duration constituting 25 minutes. After that, in post operational period reamberine infusion is continued in the same dose during 8 days. Simultaneously for 3 days after operation intravenous blood irradiation is realised. From the 4-th day of post-operative period for five days reamberine infusions 1 time per day are combined with transdermal laser irradiation of operated kidney projection with duration 10 minutes. Then, without stopping reamberine infusion, biologically active points, connected with heart meridian C1, C2, C3, C4, C5, C6, C7, C8, C9, sympathetic point of heart meridian V15, ear points AP19, AP21, AP60, AP100, AP105, AP115 are successively exposed to laser irradiation.EFFECT: method ensures effective prevention of cardiovascular complications due to reduction of level of toxic action of products of peroxide oxidation of lipids on myocardium, which makes it possible to improve functional state of myocardium.1 tbl, 1 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2612804-C2 |
| priorityDate | 2012-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 40.